These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27213997)

  • 41. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review.
    Durán J; Bockorny M; Dalal D; LaValley M; Felson DT
    Ann Rheum Dis; 2016 Sep; 75(9):1595-8. PubMed ID: 27091836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
    Finckh A; Dehler S; Gabay C;
    Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.
    Curtis JR; Bykerk VP; Aassi M; Schiff M
    J Rheumatol; 2016 Nov; 43(11):1997-2009. PubMed ID: 27803341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
    van der Heijde D; Klareskog L; Rodriguez-Valverde V; Codreanu C; Bolosiu H; Melo-Gomes J; Tornero-Molina J; Wajdula J; Pedersen R; Fatenejad S;
    Arthritis Rheum; 2006 Apr; 54(4):1063-74. PubMed ID: 16572441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
    Saraux A; Devauchelle-Pensec V; Engerran L; Flipo RM
    J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
    Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
    Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
    Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
    Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parenteral methotrexate for the treatment of rheumatoid arthritis.
    Yazici Y; Bata Y
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study.
    Manara M; Bianchi G; Bruschi E; Azzolini V; Belai Beyene N; Corbanese S; De Gennaro F; Martin-Martin LS; Molica Colella AB; Pozzi MR; Romeo N; Rossini T; Severino A; Sinigaglia L
    Clin Exp Rheumatol; 2016; 34(3):473-9. PubMed ID: 27050478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients.
    Pasma A; den Boer E; van 't Spijker A; Timman R; van den Bemt B; Busschbach JJ; Hazes JM
    Rheumatology (Oxford); 2016 Oct; 55(10):1812-9. PubMed ID: 27354686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.